What Alloplex Biotherapeutics does

Alloplex Biotherapeutics is a privately held, clinical-stage biotechnology company founded in 2016 in Boston, Massachusetts by Harvard-trained immunologist Dr. Frank Borriello, with a wholly owned Australian subsidiary (Alloplex Australia Pty Ltd, registered 2019, based in Adelaide). The company has developed a proprietary immune cell training platform called ENLIST (ENgineered Leukocyte Immune STimulator), which uses engineered allogeneic tumor cell lines expressing multiple immunomodulatory ligands to activate patient-derived peripheral blood mononuclear cells (PBMCs) via a simple ex vivo co-incubation process. This process yields SUPLEXA, an autologous, non-engineered cellular therapy composed of highly activated NK, NKT, alpha-beta, and gamma-delta T cells that exhibits broad tumor-specific cytolytic activity while sparing normal cells through a multimodal mechanism encompassing direct tumor lysis, antigen presentation, and amplification of the host anti-tumor immune response.

The company's lead clinical-stage asset, SUPLEXA, completed a first-in-human Phase 1 trial (SUPLEXA-101, NCT05237206) in Australia in July 2024, enrolling 35 patients with heavily pre-treated metastatic solid tumors including CRC-dMMR/MSI-H, ccRCC, melanoma, lung cancer, and TNBC. The trial achieved all prespecified endpoints with zero drug-related serious adverse events across more than 220 administered doses and demonstrated one complete response, two partial responses in CRC-dMMR/MSI-H and ccRCC, and durable stable disease extending beyond 70 weeks in some patients. Manufacturing is GMP-compatible, defined, and scalable, requiring only a 50ml blood draw and approximately one month of processing using standard laboratory equipment, with no genetic engineering or feeder cells required. The company received FDA Fast Track Designation in May 2026 for SUPLEXA in MSI-H colorectal cancer and submitted an IND in February 2026 to enable a US-based Phase 2 trial.

Alloplex is pre-revenue and operates with a small senior management team of four officers (CEO, CSO, CDO, and acting CFO). Its business model is partnership-driven: future revenue is expected to come from sales of SUPLEXA upon regulatory approval (one-time treatment economics) combined with potential licensing royalties from the ENLIST platform, including pharma collaborations targeting CAR-T augmentation, immune checkpoint inhibitor combinations, and non-CAR co-development. The company has raised approximately $21.2 million cumulatively across a 2019 seed, an August 2021 strategic investment of $1 million from Daewoong Pharmaceutical and HanAll BioPharma, and a Series A that launched in April 2021 and closed in February 2023 at roughly $20 million against a $25 million target. Operating geographies currently span Massachusetts (US headquarters and laboratories) and South Australia/Queensland (clinical operations), with near-term plans to initiate US-based Phase 2 trials and pursue strategic pharmaceutical partnerships to advance the program.

Name

Alloplex Biotherapeutics

Legal name

Alloplex Biotherapeutics Inc.

Website

https://alloplexbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Alloplex Biotherapeutics is a Boston-based clinical-stage biotech developing SUPLEXA, an autologous non-engineered cellular therapy generated through its proprietary ENLIST immune cell training platform, targeting relapsed/refractory solid tumors and hematologic malignancies. The company is pre-revenue and pursues a partnership-driven go-to-market model with pharma.

Ownership category

akta.pro rank

Product category

Cellular Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Cellular immunotherapy
• Autologous cell therapy
• Immuno-oncology platform
• Solid tumor therapy
• Engineered cell lines

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Autologous Cellular Therapy (SUPLEXA): Alloplex is a clinical-stage biotechnology company developing SUPLEXA, an autologous non-engineered cellular therapy. The company has not yet commercialized any product. Revenue will come from the sale of its cellular therapy product upon regulatory approval.
2. Strategic Partnerships and Licensing: The company seeks strategic partnerships with pharmaceutical companies to augment existing CAR-T programs, explore combination therapies, and collaborate on non-CAR approaches. Potential licensing revenue from ENLIST platform technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Alloplex Biotherapeutics is a clinical-stage biotechnology company developing SUPLEXA, an autologous, non-engineered cellular therapy produced via its proprietary ENLIST immune cell training platform. The platform uses engineered allogeneic tumor cell lines to activate patient-derived PBMCs ex vivo into SUPLEXA therapeutic cells (activated NK, NKT, alpha-beta and gamma-delta T cells) that demonstrate broad tumor-specific cytolytic activity across multiple solid tumor types while sparing normal cells. The company is currently preparing for Phase 2 trials following Phase 1 completion and FDA Fast Track Designation in MSI-H colorectal cancer.

Product overview

Alloplex Biotherapeutics has developed a differentiated, non-engineered cellular therapy platform comprising two key components: the ENLIST (ENgineered Leukocyte Immune STimulator) platform and the lead product SUPLEXA. ENLIST is a proprietary immune cell training technology that uses engineered tumor cell lines to activate patient-derived PBMCs through synergistic immunomodulatory signals, converting them into SUPLEXA therapeutic cells. SUPLEXA is an autologous, non-engineered cellular therapy comprising highly activated lymphoid immune cells (NK, NKT, alpha-beta and gamma-delta T cells) demonstrating broad anti-tumor cytolytic activity. The platform is currently in clinical development with SUPLEXA-101 Phase 1 completed and Phase 2 trials planned for early 2025, targeting multiple solid tumor indications including colorectal cancer (MSI-H) where FDA Fast Track Designation was received in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• SUPLEXA SUPLEXA is an autologous, non-engineered cellular therapy derived from patient peripheral blood mononuclear cells (PBMCs). It comprises highly activated lymphoid immune cells — NK, NKT, alpha-beta T and gamma-delta T cells — that demonstrate broad tumor-specific cytolytic activity across multiple solid tumor types while sparing normal cells. The multimodal mechanism coordinates direct tumor lysis, antigen presentation, and amplification of the host anti-tumor response. Lead target indications include MSI-H colorectal cancer (FDA Fast Track Designation granted May 2026), clear cell renal cell carcinoma, melanoma, lung cancer, and triple-negative breast cancer.
• ENLIST Immune Cell Training Platform The ENLIST (ENgineered Leukocyte Immune STimulator) platform is Alloplex's proprietary immune cell training technology. It uses engineered allogeneic tumor cell lines expressing multiple immunomodulatory protein ligands to engage naturally occurring receptors on patient-derived PBMCs during a simple ex vivo co-incubation step, converting them into SUPLEXA therapeutic cells. The platform is GMP-compatible, defined, requires only standard laboratory equipment, no feeder cells, and no genetic engineering of patient cells. It is also compatible with allogeneic, CAR-integrated, and iPSC-derived extensions.

Quantifiable outcome

• Zero drug-related serious adverse events (SAEs) across >220 administered doses in Phase 1 SUPLEXA-101 trial (35 patients)
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Paul SowyrdaminorOthers · 1 August 2024Appointed to Alloplex's Corporate Board in August 2024. Paul Sowyrda has over 30 years of experience in pharmaceutical and biotech sectors, having co-founded Novellus, Inc. and held leadership roles at CIBA, Dusa Pharmaceuticals, Chiron Corporation, and Brooklyn ImmunoTherapeutics.
• Cancer Research SA (CRSA)coreStrategic or Co-development Partner · 1 April 2022Phase 1 SUPLEXA-101 clinical trial site. Assoc. Professor Rohit Joshi served as Principal Investigator. Site opened April 2022 in Adelaide, South Australia.
• Southern Oncology Clinical Research Unit (SOCRU)coreStrategic or Co-development Partner · 1 April 2022Third clinical trial site for SUPLEXA-101, opened December 2022. Located in Adelaide, South Australia. Contributed to patient enrollment in the Phase 1 trial.
• Gallipoli Research Medical FoundationcoreStrategic or Co-development Partner · 1 April 2022Phase 1 SUPLEXA-101 clinical trial site. Dr. Jeff Goh served as Principal Investigator. Located at Greenslopes Hospital in Brisbane, Queensland, Australia.
• Dr. Jennifer Brown (Dana-Farber Cancer Institute)minorStrategic or Co-development Partner · 1 March 2021Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute, collaborated with Alloplex on research showing SUPLEXA cells can be manufactured from CLL patient PBMCs. Results were presented at ASCO 2021. Dr. Brown was appointed to Alloplex's Scientific Advisory Board in March 2022.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Immatics: Immatics is a clinical-stage TCR-based immunotherapy company developing adoptive cell therapies and TCR bispecifics for solid tumors. Comparable to Alloplex in solid tumor cell therapy focus and TCR/cell therapy approach.
• Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies for solid tumors (Tecelra approved for synovial sarcoma). It directly competes with Alloplex in the cell therapy for solid tumors space and is a natural comparison for both clinical strategy and partnership potential.
• Iovance Biotherapeutics: Iovance is the leading commercial TIL (tumor-infiltrating lymphocyte) therapy company for solid tumors, with FDA-approved lifileucel for melanoma. It is the closest direct competitor to Alloplex in autologous cell therapy for solid tumors, sharing the autologous manufacturing model and solid tumor focus.
• Fate Therapeutics: Fate Therapeutics develops iPSC-derived NK and T-cell therapies for cancer. It is comparable to Alloplex as a next-generation cell therapy platform company pursuing solid and hematologic tumors with an off-the-shelf manufacturing thesis.
• Nkarta: Nkarta is developing allogeneic and autologous CAR-NK cell therapies for hematologic malignancies and solid tumors. It is comparable to Alloplex in the engineered/non-engineered cell therapy for oncology category, with overlapping indication ambitions.

Emerging players

• Cellectis: Cellectis is a clinical-stage gene-edited allogeneic CAR-T platform company. Comparable as an emerging cell therapy platform peer pursuing both autologous and allogeneic cell engineering approaches for oncology.
• Senti Biosciences: Senti Biosciences is developing next-generation cell therapies with gene circuit technology for oncology. Comparable as an early-stage cell therapy platform pursuing solid tumor indications with novel engineering or programming approaches.
• Caribou Biosciences: Caribou is a clinical-stage cell therapy company using CRISPR genome editing for allogeneic CAR-T and CAR-NK therapies. It is comparable as a next-generation cell therapy platform peer, though focused on hematologic malignancies rather than solid tumors.

Broad incumbents

• Legend Biotech: Legend Biotech is a commercial-stage cell therapy company (Carvykti, BCMA CAR-T with Janssen) and a broader incumbent in the engineered cell therapy space. Comparable as a cell therapy commercial benchmark, though focused on hematologic rather than solid tumors.
• Allogene Therapeutics: Allogene is a well-capitalized leader in allogeneic CAR-T cell therapy. While its allogeneic approach contrasts with Alloplex's autologous model, both compete in cell therapy for cancer and Allogene's clinical and manufacturing experience sets the industry benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alloplex-biotherapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alloplex Biotherapeutics